Eurobio Scientific - Public Comps and Valuation Multiples

Eurobio Scientific Overview

About Eurobio Scientific

Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium.

Founded

2018

HQ

Employees

127

Website

exonhit.com

Sectors

Laboratory Services
Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $195M

LTM EBITDA $32.1M

EV

$266M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Eurobio Scientific Financials

As of December 2025, Eurobio Scientific reported last 12-month revenue of $195M and EBITDA of $32.1M.

In the same period, Eurobio Scientific achieved $9.3M in LTM net income.

See Eurobio Scientific valuation multiples based on analyst estimates

Eurobio Scientific P&L

In the most recent fiscal year, Eurobio Scientific reported revenue of $179M and EBITDA of $31.9M.

Eurobio Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Eurobio Scientific valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$195M	XXX	$179M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$83.1M	XXX	XXX	XXX
Gross Margin	n/a	XXX	46%	XXX	XXX	XXX
EBITDA	$32.1M	XXX	$31.9M	XXX	XXX	XXX
EBITDA Margin	16%	XXX	18%	XXX	XXX	XXX
EBIT	$27.6M	XXX	$11.4M	XXX	XXX	XXX
EBIT Margin	14%	XXX	6%	XXX	XXX	XXX
Net Profit	$9.3M	XXX	$4.6M	XXX	XXX	XXX
Net Margin	5%	XXX	3%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Eurobio Scientific including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $195M. EBITDA for the last twelve months was $32.1M. In the most recent fiscal year, Eurobio Scientific achieved $179M in revenue and $31.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$195M	Analyst estimates available to subscribers	$179M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$83.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	46.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$32.1M	Analyst estimates available to subscribers	$31.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	16.4% EBITDA margin	Analyst estimates available to subscribers	17.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$27.6M	Analyst estimates available to subscribers	$11.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	14.1% EBIT margin	Analyst estimates available to subscribers	6.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$9.3M	Analyst estimates available to subscribers	$4.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	4.8% net profit margin	Analyst estimates available to subscribers	2.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Eurobio Scientific

This financial data table provides comprehensive performance metrics for Eurobio Scientific, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Eurobio Scientific generated $195M in revenue over the last twelve months.
The company achieved $32.1M in EBITDA over the last twelve months.
Net income over the last twelve months reached $9.3M.

Fiscal Year Performance

In the most recent fiscal year, Eurobio Scientific reported $179M in total revenue.
Fiscal year EBITDA was $31.9M.
The company maintained a gross profit margin of 46.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 17.8%.
Net profit margin reached 2.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Eurobio Scientific. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Eurobio Scientific Stock Performance

Eurobio Scientific has current market cap of EUR 240M (or $278M), and EV of EUR 230M (or $266M).

Market Cap Evolution

Eurobio Scientific Stock Data

As of January 19, 2026, Eurobio Scientific's stock price is EUR 24 (or $28).

See Eurobio Scientific trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$266M	$278M	XXX	XXX	XXX	XXX	$0.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Eurobio Scientific Valuation Multiples

Eurobio Scientific's trades at 1.4x EV/Revenue multiple, and 8.3x EV/EBITDA.

See valuation multiples for Eurobio Scientific and 15K+ public comps

Eurobio Scientific Financial Valuation Multiples

As of January 19, 2026, Eurobio Scientific has market cap of $278M and EV of $266M.

Equity research analysts estimate Eurobio Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Eurobio Scientific has a P/E ratio of 30.0x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$278M	XXX	$278M	XXX	XXX	XXX
EV (current)	$266M	XXX	$266M	XXX	XXX	XXX
EV/Revenue	1.4x	XXX	1.4x	XXX	XXX	XXX
EV/EBITDA	8.3x	XXX	8.3x	XXX	XXX	XXX
EV/EBIT	9.6x	XXX	9.6x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	30.0x	XXX	30.0x	XXX	XXX	XXX
EV/FCF	13.2x	XXX	13.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eurobio Scientific Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Eurobio Scientific Margins & Growth Rates

Eurobio Scientific's last 12 month revenue growth is 4%

Eurobio Scientific's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.6M for the same period.

Eurobio Scientific's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Eurobio Scientific's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Eurobio Scientific and other 15K+ public comps

Eurobio Scientific Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	4%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	16%	XXX	16%	XXX	XXX	XXX
EBITDA Growth	17%	XXX	4%	XXX	XXX	XXX
Rule of 40	24%	XXX	21%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	28%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	19%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	40%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial